IRVINE, CA -- (MARKET WIRE) -- September 26, 2006 -- Dermisonics, Inc. (OTCBB: DMSI) (FWB: FQC), a developer of painless injection-free ultrasonic transdermal drug delivery patches and technologies with broad pharmaceutical and consumer applications, announced today that it successfully completed its HPT-3A human pilot trial of its proprietary U-Strip transdermal drug delivery system in patients with Type-2 diabetes, demonstrating that an insulin-loaded proprietary patch does not cause skin damage or irritation.
